Explore the latest developments concerning Prediction: Buying Pfizer.
Prediction: Buying Pfizer Stock Today Could Set You Up for Life
Pfizer (NYSE: PFE) investors got some very bad news when the company was forced to abandon its internally developed GLP-1 weight loss drug in April, 2025. With patent expirations on the horizon, falling even further behind competitors like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in an emerging new drug niche was a bad look. However, what happened next is what's really important.
GLP-1 drugs have seen strong consumer demand. Eli Lilly's industry-leading GLP-1 drugs Mounjaro and Zepbound, for example, saw revenue growth of 99% and 175%, respectively, in 2025. The flameout of Pfizer's internally generated GLP-1 candidate was a major setback.
Pfizer Inc (PFE): Our Calculation of Intrinsic Value
Each week we run a DCF (Discounted Cash Flow) model on a company from our watchlist.
Pfizer is one of the world’s largest pharmaceutical companies, focused on developing and commercializing medicines and vaccines across oncology, immunology, cardiology, and infectious diseases.
The company gained global prominence during the COVID-19 pandemic through its vaccine and antiviral treatments, which temporarily drove exceptional revenue and cash flow. However, Pfizer has since entered a post-pandemic normalization phase.
Pfizer operates through a research-driven, patent-based model, where profitability depends on:
Pfizer is transitioning back to a traditional large-cap pharma profile: slower growth, patent cliffs, and reliance on pipeline execution.
Oxygen Bubble Pen CO2 Oxygen Portable Facial Machine CO2 Gel Facial Skin Care Device Facial SPA CO2 Bubble Oxygen Beauty Machine
Why Pfizer Remains A Strong Buy In 2026 (NYSE:PFE)
After Pfizer's Q4 report (PFE), which, as you know, was published on February 3, its stock was up 7%, outperforming the S&P 500 (SPY) [-5.7% return]. (These results came in after my last update on Pfizer, which was in
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
For more detailed information, explore updates concerning Prediction: Buying Pfizer.
0 Comments